Remove Clinical Development Remove DNA Remove Protein Expression Remove Small Molecule
article thumbnail

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

Several viral vectors are being used currently, in addition to non-viral vectors, such as oligonucleotides, naked DNA, and lipoplexes and polyplexes. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Michael Traxlmayr, PhD, Group leader, CD Laboratory for Next-Generation CAR T Cells, University of Natural Resources & Life Sciences, on: ‘Novel concepts to regulate CAR T cell activity with small molecule drugs in vivo’.